According to market research, the mitochondrial therapeutics market is valued at $2.32 billion in 2025. It is projected to reach $5.4 billion by 2035, growing at a CAGR of 8.8%, primarily driven by advances in gene therapy, enzyme replacement therapies and pharmacological agents, including drugs that modulate oxidative phosphorylation and mitochondrial biogenesis (Figure 1). 22 December 2025
A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new opportunities for pharma growth. 15 November 2024
According to market research, the mitochondrial therapeutics market is valued at $2.32 billion in 2025. It is projected to reach $5.4 billion by 2035, growing at a CAGR of 8.8%, primarily driven by advances in gene therapy, enzyme replacement therapies and pharmacological agents, including drugs that modulate oxidative phosphorylation and mitochondrial biogenesis (Figure 1). 22 December 2025
A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new opportunities for pharma growth. 15 November 2024
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
An analysis of the recent investment activity in antibody–drug conjugates (ADCs) prior to Pfizer's newly-announced $43 billion takeover of Seagen. 13 March 2023
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage US biotechnology company developing precisely targeted small molecule kinase inhibitors for cancer, with lead programs in ROS1- and ALK-positive non-small cell lung cancer.